

The Endocrine Activity Index (EAI) is a gene expression profiling test that measures endocrine activity in tumors from patients with hormone receptor-positive HER2-negative Stage I-III breast cancer.

With the results from EAI you and your doctor can further understand:

- your risk of recurrence
- benefit from a dose-intense treatment (if your doctor is considering chemotherapy)
- benefit from extended endocrine therapy

No other test in the market comprehensively analyzes the estrogen and progesterone related hormone signaling pathway.



For more details about our products please visit:
delphi-diagnostics.com

For medical related questions please contact your treating provider

For all other questions regarding testing please contact:
support@delphi-diagnostics.com
p. 281.896.0056



Endocrine Activity Index™

© 2026 Delphi Diagnostics, Inc. All rights reserved. Delphi Diagnostics, Endocrine Activity Index, and EAI are registered trademarks of Delphi Diagnostics in the US and other jurisdictions.



When My Doctor Orders an EAI Test



STEP ONE

When your doctor orders a test, Delphi's laboratory requests a **sample of your tumor tissue** to be sent to us



STEP TWO

When the tissue is received, **testing is performed**



STEP THREE

Your results are **reviewed and a final report is created** and then released



STEP FOUR

Your doctor will **discuss the next steps in your care** informed by the EAI results

What Information Will This Test Provide?

EAI

If your doctor is considering chemotherapy, EAI can help determine when dose-intense chemotherapy delivers meaningful benefit.

If your doctor is considering endocrine therapy, EAI can help determine if you may benefit from extending endocrine therapy for >5 years.

EAI Recurrence Risk (EAI_{RR})

Provides information on your prognosis, including the likelihood of your tumor coming back.

1. Speers CW, et al. J Clin Oncol. 2023;41(10):1841-1848. DOI: 10.1200/JCO.22.01499.
2. Metzger Filho O, et al. J Clin Oncol. 2025 Apr;43(10):1229-1239. DOI: 10.1200/JCO-24-01875. PMID: 39746162.
3. Penault-Llorca F, et al. Eur J Cancer (2025). DOI: 10.1016/j.ejca.2025.116152
4. Mamounas EP, et al. Clin Cancer Res (2026) 32(4_Supplement):GS3-05. DOI: 10.1158/1557-3265.SABCS25-GS3-05

The entire process can take **up to 14 days** from when the sample is received in step 2 above.

Frequently Asked Questions

What makes the EAI test different?

The EAI test provides information to help guide treatment decisions beyond what other breast cancer genomic tests can provide. Information about your prognosis, and benefit from extended endocrine therapy and dose-dense chemotherapy benefits.

What is "endocrine activity"?

Endocrine activity is a term to describe how active genes related to estrogen and progesterone are in your tumor.

Will I get a copy of my report?

You may receive a copy of your report from your doctor or you may contact the support team at Delphi Diagnostics to receive a copy directly.

How much will this cost?

Delphi Diagnostics will bill your insurance company for testing, we also offer a patient financial assistance program to those who qualify. Please contact us to learn more.

Will I need Chemotherapy?

If your doctor is considering chemotherapy, the EAI test can help your doctor determine if a standard dose regimen or a dose-dense regimen may be best for you.